当前位置: X-MOL 学术Stem Cells Transl. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer.
STEM CELLS Translational Medicine ( IF 5.4 ) Pub Date : 2020-05-16 , DOI: 10.1002/sctm.19-0423
May Sabry 1 , Mark W Lowdell 1
Affiliation  

Adoptive cell therapy (ACT) is an approach to cancer treatment that involves the use of antitumor immune cells to target residual disease in patients after completion of chemo/radiotherapy. ACT has several advantages compared with other approaches in cancer immunotherapy, including the ability to specifically expand effector cells in vitro before selection for adoptive transfer, as well as the opportunity for host manipulation in order to enhance the ability of transferred cells to recognize and kill established tumors. One of the main challenges to the success of ACT in cancer clinical trials is the identification and generation of antitumor effector cells with high avidity for tumor recognition. Natural killer (NK) cells, cytokine‐induced killers and natural killer T cells are key innate or innate‐like effector cells in cancer immunosurveillance that act at the interface between innate and adaptive immunity, to have a greater influence over immune responses to cancer. In this review, we discuss recent studies that highlight their potential in cancer therapy and summarize clinical trials using these effector immune cells in adoptive cellular therapy for the treatment of cancer.

中文翻译:

十字路口的杀手:先天免疫细胞在癌症的过继细胞治疗中的应用。

过继细胞疗法(ACT)是一种癌症治疗方法,涉及在化学/放射疗法完成后使用抗肿瘤免疫细胞靶向患者中的残留疾病。与癌症免疫疗法中的其他方法相比,ACT具有许多优势,包括能够在选择过继转移之前在体外特异性扩增效应细胞,以及进行宿主操作以增强转移细胞识别和杀死已建立细胞的能力的机会。肿瘤。ACT在癌症临床试验中成功的主要挑战之一是鉴定和生成具有高亲和力的抗肿瘤效应细胞以用于肿瘤识别。自然杀伤(NK)细胞,细胞因子诱导的杀伤细胞和自然杀伤性T细胞是癌症免疫监测中的关键先天或先天性效应细胞,它们作用于先天免疫和适应性免疫之间的界面,从而对癌症的免疫反应产生更大的影响。在这篇综述中,我们讨论了近期的研究,这些研究着重介绍了其在癌症治疗中的潜力,并总结了在过继性细胞疗法中使用这些效应免疫细胞治疗癌症的临床试验。
更新日期:2020-05-16
down
wechat
bug